



Workshop Agenda

January 19-21, 2000



Wednesday, January 19 – Briefing Day

9:00 a.m. – 9:30 a.m. Arrival and Check-In

Session A

9:30 a.m. – 10:00 a.m. Opening Session
Welcome and Charge to Group Alan Rabson, M.D.
Mike Sage, M.P.H.
Ground Rules and Introductions Denise Cavanaugh, Facilitator

Session B

10:00 a.m. – 10:45 a.m. Broad Overview and History Mark Epstein, Moderator
Brief NTS History Mark Epstein
A Citizen's Perspective Trisha Pritikin, Esq., M.D., O.T.R.
IOM Report Robert Lawrence, M.D.

10:45 a.m. – 11:00 a.m. Break

Session C

11:00 a.m. – 12:30 p.m. The Science of I-131 Exposure and Health

1. What Can Science Tell Us About the Health Risks of I131? Charles Land, Ph.D.
2. What I-131 Doses Did People Receive From NTS Fallout? Steve Simon, Ph.D.
3. Reflections From and Independent Scientist on the Science of I-131. Owen Hoffman, Ph.D.

12:30 p.m. – 1:45 p.m. Lunch

Session D

1:45 p.m. – 2:15 p.m. Public Health Communications Challenge Elaine Arkin

Session E

2:15 p.m. – 3:00 p.m. Table Discussions Denise Cavanaugh

3:00 p.m. – 3:15 p.m. Break

Wednesday, January 19 – Briefing Day (Continued)

Session F

3:15 p.m. – 5:15 p.m. Communications Challenge: Group Discussions

1. Interest Group Perspectives

Moderator	Seth Tuler
State/Local Advocacy Organization	J. Truman
National Advocacy Organization	Maureen Eldredge
Physician Advocate	Tim Takaro, M.D.
Native American	Robert Holden
Ground Zero	Lincoln Grahlf, Ph.D.
Consumer Organization	Jean Halloran

2. Health Provider: Channels and Gatekeepers

Moderator	Kevin Teale, M.A.
Practitioner	R. Michael Tuttle, M.D.
Sliding Scale Clinic	Delvin Little, M.D.
Medical Specialty Group	Henry Royal, M.D.
Risk Communicator	Jim Flynn, Ph.D.
Medical Ethicist	Kristin Shrader-Frechette, Ph.D.

Session G

5:15 p.m. – 5:45 p.m. Wrap-Up

Denise Cavanaugh

5:45 p.m. – 6:30 p.m. Break

Session H

6:30 p.m. – 9:00 p.m. Networking Reception and Dinner

Thursday, January 20 – Discussion Day

7:30 a.m. – 8:30 a.m. Continental Breakfast

Session I

8:30 a.m. – 8:45 a.m. Summary of Day 1 and Charge for Day 2 Denise Cavanaugh

Session J

8:45 a.m. – 10:15 a.m. Screening/Medical Monitoring Denise Cavanaugh
Mark Epstein
Moderators

1. What Recommendations and Current Programs Exist for Screening and Monitoring? Robert Spengler, Sc.D.
R. Michael Tuttle, M.D.
2. Assessing Individual Risk Keith Baverstock, Ph.D.
Owen Hoffman, Ph.D.
3. A Model for Individual Decisionmaking Valerie Fiset, R.N., M.Sc.N.

10:15 a.m. – 10:30 a.m. Break

Session K

10:30 a.m. – 12:00 noon Table Discussions:
What do we know that we can use to begin developing messages and defining populations?
What do we need to know to develop and effective campaign?
What questions should be forward for April screening forum?

12:00 noon – 1:15 p.m. Lunch

Session L

1:15 p.m. – 3:30 p.m. Developing Model Outreach

1. Strategies for Message Development Peter Sandman, Ph.D.
An approach to identifying Target audiences
Considerations for developing Science-based messages Neil Weinstein, Ph.D.
2. Audiences Research Results Ed Maibach, Ph.D.
Presentation of preworkshop research

3:30 p.m. – 3:45 p.m. Break

Thursday, January 20 – Discussion Day (Continued)

Session M

3:45 p.m. – 5:15 p.m. Developing Model Outreach (Continued)
3. Table Discussions Ed Maibach, Ph.D., Facilitator
What additional audience research is needed?

Session N

5:15 p.m. – 5:45 p.m. Wrap-Up Denise Cavanaugh
Identify agreements and outstanding issues.
Move forward on a communications plan.

Friday, January 21 – Input Day

7:30 a.m. – 8:30 a.m. Continental Breakfast

Session O

8:30 a.m. – 9:00 a.m. Summary of Day 2 and Charge for Day 3 Denise Cavanaugh
Review Operating Principles

Session P

9:00 a.m. – 11:00 Breakout Session
Topic Decided on Thursday Afternoon

10:00 a.m. – 10:15 a.m. Break

Session Q

11:00 a.m. – 12:00 noon Reports From Breakout Session Group
Reporters

12:00 noon – 1:00 p.m. Lunch

Session R

1:00 p.m. – 2:00 p.m. Summary James Mathews/Kellie Marciel
Joan Morrissey
Next Steps Nelvis Castro
Owen Devine

Session T

2:00 p.m. – 2:15 p.m. Closings Comments and Thank You to Alan Rabson, M.D.
Participants